Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-067279
Filing Date
2025-05-09
Accepted
2025-05-08 18:01:35
Documents
63
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q nktr-20250331.htm   iXBRL 10-Q 1887370
2 EX-31.1 nktr-ex31_1.htm EX-31.1 14858
3 EX-31.2 nktr-ex31_2.htm EX-31.2 15086
4 EX-32.1 nktr-ex32_1.htm EX-32.1 10796
  Complete submission text file 0000950170-25-067279.txt   7504383

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT nktr-20250331.xsd EX-101.SCH 1210859
66 EXTRACTED XBRL INSTANCE DOCUMENT nktr-20250331_htm.xml XML 1096051
Mailing Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158
Business Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300
NEKTAR THERAPEUTICS (Filer) CIK: 0000906709 (see all company filings)

EIN.: 943134940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-24006 | Film No.: 25927674
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)